A New Dawn for Transplants: Deceased Donor Marrow Shows Promise

SAN FRANCISCO, CA – January 23, 2026 – The world of cellular therapy is poised for a significant development as San Francisco-based biotech company Ossium Health prepares to unveil first-in-human clinical data for its revolutionary 'off-the-shelf' bone marrow transplant platform. The data, sourced from the ongoing PRESERVE I study, will be presented at the upcoming 2026 Tandem Meetings in Salt Lake City, offering a promising new horizon for patients with life-threatening blood cancers who are in desperate need of a transplant.

Ossium Health is pioneering the use of cryopreserved bone marrow collected from deceased organ donors, creating a bank of ready-to-use grafts. This approach directly confronts one of the most persistent and heartbreaking challenges in modern medicine: the search for a matching donor. The company's presentation could mark a pivotal moment, potentially transforming bone marrow transplantation from a race against time dependent on a living donor to a readily accessible, on-demand therapy.

The Race Against Time for Transplant Patients

For decades, a bone marrow transplant has been a lifesaving, last-resort treatment for patients with aggressive hematologic malignancies like leukemia and lymphoma. The procedure replaces a patient's diseased marrow with healthy hematopoietic stem cells, which can rebuild a new, healthy blood and immune system. However, the success of this process hinges on finding a genetically compatible donor.

This search is fraught with difficulty. Despite global registries containing millions of volunteers, a staggering number of patients never find a suitable match. Studies indicate that up to 45% of patients who need a transplant are unable to receive one, often because a viable donor cannot be identified. The challenge is even more acute for individuals from ethnic minority backgrounds, whose genetic diversity is underrepresented in donor pools. For instance, Black or African American patients have only a 29% chance of finding a match through the National Marrow Donor Program (NMDP).

Even when a match is found, the process is far from guaranteed. The living donor may become unavailable for health or personal reasons, or the logistical complexities can introduce critical delays. For patients whose cancer is progressing rapidly, any delay can be the difference between a chance at remission and disease relapse. An 'off-the-shelf' product, pre-screened, tested, and stored for immediate use, could eliminate these hurdles entirely.

PRESERVE I: A Glimpse into the Future of Transplants

At the Tandem Meetings, a premier global forum for transplantation science, Ossium Health's Chief Medical Officer, Dr. Sagar Munjal, will deliver an oral presentation detailing the experience of the first four patients treated in the PRESERVE I clinical trial. This first-in-human study (NCT05589896) is evaluating the safety and feasibility of transplanting Ossium’s cryopreserved marrow into adults with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).

The preliminary findings are expected to demonstrate that transplanting bone marrow from deceased donors is both safe and feasible, a crucial first step in validating the entire platform. According to the company, these initial results are encouraging and support the transformative potential of their technology.

In addition to the main oral presentation, Ossium will present three posters that further underscore the platform's advantages. One poster details a powerful case study: the “First Report of Successful, Lifesaving and Timely Graft Rescue Using an Off-the-Shelf Cryopreserved, Cadaveric Marrow.” This case involved a patient whose planned living donor unexpectedly became unavailable, a scenario that is often a death sentence. The immediate availability of Ossium's banked marrow provided a lifesaving alternative. Other posters will highlight the potential for high-dose marrow from deceased donors to reduce relapse risk and demonstrate the technical feasibility of reprocessing and refreezing the product, adding to its logistical flexibility.

Building a Bank of Hope

Ossium Health’s innovation lies not just in the concept but in the execution. The company has developed a proprietary process to harvest hematopoietic stem cells from the vertebral bodies of deceased individuals who consented to organ donation—a source that was previously untapped. This marrow is then processed, tested to regulatory standards, and cryopreserved in a clinical-grade bank, creating a inventory of transplantable units.

This novel approach has also led to a unique regulatory path. The U.S. Food and Drug Administration (FDA) has concluded that Ossium's product is not fundamentally different from bone marrow derived from living donors. Consequently, the PRESERVE I study is not being conducted under a typical Investigational New Drug (IND) application, potentially signaling a more streamlined path to widespread clinical use if comparability is firmly established.

To ensure this innovation reaches patients, Ossium has forged a strategic partnership with the NMDP/Be The Match, the organization that manages the world's largest and most diverse marrow registry. This collaboration aims to integrate Ossium's banked marrow into the existing transplant infrastructure, allowing transplant centers to search for and request these off-the-shelf units seamlessly. The company has also established a compassionate use initiative, the HOPE Program, to provide access to patients who fall outside the clinical trial's criteria.

Experts Weigh In on a Potential 'Game Changer'

The medical community is watching these developments with keen interest. One leading hematologist at a major cancer institute, not involved in the study, called the use of banked deceased donor grafts an “exciting step toward improving transplant access” for patients with aggressive blood cancers. He noted that this approach could significantly shorten wait times and broaden transplant availability, especially for patients struggling to find a living donor.

Another transplant specialist described the ability to use a deceased donor's marrow as a “pioneering achievement” that “presents a whole new set of opportunities for our patients.” This expert emphasized the profound impact it could have on addressing the stark racial disparities in donor matching.

“These presentations highlight the growing clinical body of evidence supporting the feasibility, safety, and transformative potential of Ossium bone marrow,” said Kevin Caldwell, CEO and Co-Founder of Ossium Health, in a statement. “We look forward to sharing insights from PRESERVE I and related clinical experience with the transplant community at Tandem.”

While other advanced therapies like CAR-T and gene editing are revolutionizing cancer treatment, they don't eliminate the need for traditional stem cell sources in many contexts. Ossium's platform is not necessarily a competitor to these therapies but rather a fundamental improvement to the transplant procedure itself, making it more reliable, faster, and more equitable. The upcoming data from Salt Lake City will be a critical test, but if the initial promise holds, it could herald a new era where a patient's access to a lifesaving transplant is no longer a matter of luck, but a certainty.